4 Healthcare Stock Stories for the Weekend

Pfizer (NYSE:PFE): Closing price $26.54

On Friday, Pfizer said that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion concerning the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients suffering from chronic phase, accelerated phase, and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor, and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. The CHMP’s positive opinion will be evaluated by the European Commission, which has the authority to approve medicines for the EU. Pfizer expects a decision from the Commission in the coming months.


Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Life Technologies Corporation (NASDAQ:LIFE): Closing price $60.79

The company’s board has retained Deutsche Bank Securities and Moelis & Company to assist it in its annual strategic review. The board of directors has not decided on any particular course of action, however.


Zimmer Holdings (NYSE:ZMH): Closing price $73.61

Zimmer reported that it has received 510(NYSE:K) clearance from the FDA to market iASSIST Knee, called the Personalized Guidance System for knee replacement procedures. iASSIST marks a revolutionary next step in surgical guidance, supplying simple, intuitive and accurate intraoperative feedback and alignment validation to surgeons while conducting joint replacement procedures, removing the need for bulky capital equipment.


NuPathe (NASDAQ:PATH): Closing price $3.30

NuPathe has received FDA approval of the single-use, battery-powered patch Zecuity for the acute treatment of migraine with or without aura in adults. The patch actively delivers sumatriptan, which is the most widely prescribed migraine medication, through the skin. Zecuity gives relief from both migraine headache pain and migraine-related nausea.


Don’t Miss: Vivus Plunges on Downgrade, Johnson & Johnson Ties Up Loose Ends, Pfizer Initiates a Spin-Off.